Kymera Therapeutics Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding agent coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or polybromo-1 (PB1) protein targeting moiety via a linker reported to be useful for the treatment of cancer, viral infection, neurodegeneration, liver, metabolic, cardiovascular, genetic and inflammatory disorders, among others.
Researchers at Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have disclosed bicyclic substituted compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of Parkinson's disease.
Hangzhou Yirui Pharmaceutical Technology Co. Ltd. has described N-tetrazolyl aryl urea derivatives acting as bradykinin B1 receptor antagonists reported to be useful for the treatment of age-related macular degeneration, allergic conjunctivitis, pulmonary edema, neuralgia, infectious pneumonia, diabetic retinopathy, SARS-CoV-2 infection (COVID-19) and uveitis.
Treeline Biosciences Inc. has divulged proteolysis targeting chimeras (PROTACs) compounds comprising a cereblon (CRBN) binding moiety covalently bonded to a B-cell lymphoma 6 protein (BCL6) targeting moiety through a linker reported to be useful for the treatment of cancer.
Mirati Therapeutics Inc. has identified compounds acting as GTPase KRAS and/or GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.
Researchers at Aston Science Co. Ltd. and Korea Research Institute of Chemical Technology have synthesized phenylsulfonamide derivatives acting as eukaryotic translation initiation factor 2-α kinase 1 (HRI) and/or translation initiation factor 2-α kinase 3 (PERK) and/or eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer.
Guangzhou Fermion Technology Co. Ltd. has disclosed non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of cancer, asthma and more.
Shares of Corcept Therapeutics Inc. (NASDAQ:CORT) fell 26% Jan. 2 on news that a U.S. court determined that Teva Pharmaceuticals Ltd. does not infringe on patents related to use of cortisol receptor blocker Korlym (mifepristone) in Cushing’s syndrome, opening the possibility of Teva’s generic version to enter the market.
Ubidx Inc. has designed a diagnostic system comprised of a fluidic single-use disposable and a base. While the fluidic single-use disposable or cartridge is generally described as being suitable for testing a single sample, the base or hub may be used numerous times to perform numerous tests using numerous fluidic single-use disposables or cartridges.
RSS
